Retatrutide Peptide Cas No.2381089-83-2
Cov khoom siv: chemically synthesized peptides
Cov ntsiab lus ntawm cov khoom: Ntau dua lossis sib npaug li 98%
CAS Nr .: 2381089-83-2
Txoj kev kuaj pom: HPLC
Cov khoom xyaw nquag: Retatrutide
Cov lus piav qhia: Dawb rau cov khoom dawb
Khoom siv: kev tshawb fawb kev rog, hom 2 mob ntshav qab zib mechanism tshawb nrhiav
Khoom ntim: Customized raws li xav tau: 1mg / 10mg / 20mg / 50mg / 100mg / 500mg / 1g, thiab lwm yam
Cov khoom cia: -20 degree, tsaus, noo noo-pov thawj, kaw thiab qhuav
Lub neej txee: 24 lub hlis
Khoom Description

High-zoo, siab-purity Retatrutide Powder
Retarutide yog triple receptor agonist uas tuaj yeem ua kom muaj glucagon ib txhij zoo li peptide-1 receptor (GLP-1R), qabzib nyob ntawm insulin-dependent tso tawm polypeptide receptor (GIPR), thiab glucagon receptor (GCGR). Los ntawm ntau lub hom phiaj, ritaglutide tau pom muaj peev xwm zoo hauv kev tswj qhov hnyav, ntshav qabzib, thiab lub zog metabolism.
Cov khoomMuaj nuj nqi
1. Cov nyhuv poob
Tseem ceeb appetite suppression:Los ntawm activating GLP-1 thiab GIP receptors nyob rau hauv lub hauv paus paj hlwb, lub cev lub siab xav thiab noj cov zaub mov yog txo.
Txhawb kev siv hluav taws xob:Ua kom glucagon receptors, txhim kho cov metabolism thiab siv zog ntawm cov ntaub so ntswg adipose, thiab txhawb cov rog rog.
Delaying gastric emptying:Ua kom qis qis ntawm lub plab zom mov, ua kom ntev satiety, thiab txo qhov zaus ntawm kev noj mov.
2. Kev tswj cov ntshav qabzib muaj nuj nqi
Txhawb kev tsim cov tshuaj insulin:Txhim kho qhov rhiab heev ntawm pancreatic beta hlwb rau cov ntshav qab zib, txhawb kev tsim cov tshuaj insulin, thiab pab tswj cov ntshav qab zib.
Txo cov piam thaj hauv cov ntshav:Los ntawm kev ua ntau yam receptors, txhim kho postprandial ntshav qabzib hloov pauv thiab txo kev yoo mov thiab postprandial ntshav qabzib.
Txhim kho insulin tsis kam:Txhim kho lub cev rhiab heev rau insulin thiab txhawb nqa cov piam thaj metabolism sib npaug.
3. Cov txiaj ntsig zoo ntawm metabolic
Txhim kho lipid metabolism:pab txo cov ntshav lipid txawv txav, txhim kho cov ntshav lipid profile, thiab txo cov kev pheej hmoo ntawm cov kab mob plawv.
Txhim kho metabolic syndrome:Los ntawm kev tswj hwm lub cev hnyav, ntshav qabzib, thiab lipids, txo cov kab mob pathological cuam tshuam nrog metabolic syndrome.
Muaj peev xwm tiv thaiv kab mob plawv:Qee cov kev tshawb fawb tau pom tias GLP-1 thiab GIP receptor agonists tuaj yeem txhim kho cov hlab plawv thiab pab txo qis cov xwm txheej ntawm cov hlab plawv.
4. Lwm yam muaj peev xwm ua tau
Txhim kho daim siab rog ntau ntxiv:Tej zaum yuav pab txo qis cov roj ntsha hauv siab uas cuam tshuam nrog tsis yog- kab mob cawv fatty siab (NAFLD).
Txhim kho lub neej zoo:Los ntawm kev txo qhov hnyav thiab tswj cov ntshav qab zib, kev noj qab haus huv tag nrho thiab lub neej zoo ntawm cov neeg mob tuaj yeem txhim kho.
Khoom kom zoo dua
Multi receptor activation coj ntau cov kev cai metabolic cov teebmeem.
Tej zaum yuav txhim kho cov neeg mob cov tshuaj ua raws li kev noj haus thiab kev kho mob zoo.
Nws yuav dhau los ua ib tiam tshiab ntawm kev xaiv tshuaj rau kev kho mob rog thiab ntshav qab zib yav tom ntej.
Mechanism ntawm kev ua
GLP-1 receptor activation:txhawb kev tsim cov tshuaj insulin, inhibits plab hnyuv, thiab txo qis qab los noj mov.
GIP receptor activation:txhim kho pancreatic beta cell muaj nuj nqi thiab ua kom cov insulin rhiab heev.
Glucagon receptor activation:txhawb kev siv zog thiab kev rog rog, pab kom poob phaus.
Cov nyhuv synergistic ntawm triple mechanism zoo tswj cov metabolism hauv kev sib npaug, ua tiav ob qho txiaj ntsig ntawm kev poob phaus thiab txhim kho cov ntshav qab zib.
Cov khoomAppdaim ntawv qhia
1. Kev kho mob rog:
Los ntawm kev txo qis qab los noj mov thiab txhawb kev siv hluav taws xob, kev poob ceeb thawj tseem ceeb thiab ntev tuaj yeem ua tiav, txhim kho cov neeg mob cov txheej txheem metabolic thiab lub neej zoo.
2. Adjuvant kho mob ntshav qab zib hom 2:
Cov neeg mob ntshav qab zib hom 2 thiab rog rog, siv los txhim kho cov ntshav qab zib
Los ntawm kev nce cov tshuaj insulin secretion thiab txhim kho cov tshuaj insulin, cov ntshav qabzib tuaj yeem tswj tau.
3. Kev tswj xyuas metabolic syndrome:
Feem ntau manifested nyob rau hauv indications thiab kev txhim kho ntawm metabolic ntsuas
4. Muaj peev xwm siv tau:
Cov kab mob tsis muaj dej cawv fatty daim siab, indirectly txo txoj kev pheej hmoo ntawm cov kab mob plawv
Clinical application prospects
Kev kho mob rog rog:Los ntawm kev txo qis qab los noj mov thiab txhawb lub zog metabolism, qhov hnyav tuaj yeem ua tiav.
Kev tswj ntshav qab zib hom 2:Txhim kho cov ntshav qabzib tswj, nce insulin secretion thiab rhiab heev.
Metabolic Syndrome:Cia siab tias yuav txhim kho cov ntshav lipid txawv txav thiab cov kab mob plawv.
Kev tshawb fawb soj ntsuam kev vam meej
● Kev sim tshuaj ntsuam xyuas tau pom tias ritaglutide yog qhov zoo dua rau cov uas twb muaj lawm ib leeg GLP-1 receptor agonists hauv kev poob phaus.
● Kev nyab xeeb zoo, cov kev tsis zoo tshwm sim muaj xws li kev mob plab hnyuv (xws li xeev siab, ntuav, raws plab), uas feem ntau mob me me thiab ib ntus.
Cim npe nrov: Tuam Tshoj Retatrutide Peptide CAS No.2381089-83-2 Chaw tsim tshuaj paus, lwm tus neeg, Hoobkas
You Might Also Like
Xa kev nug










